Literature DB >> 23910095

Identification of small molecule inhibitors of p27(Kip1) ubiquitination by high-throughput screening.

Li-Ching Ooi1, Nobumoto Watanabe, Yushi Futamura, Shaida Fariza Sulaiman, Ibrahim Darah, Hiroyuki Osada.   

Abstract

Dysregulation of p27(Kip1) due to proteolysis that involves the ubiquitin ligase (SCF) complex with S-phase kinase-associated protein 2 (Skp2) as the substrate-recognition component (SCF(Skp2)) frequently results in tumorigenesis. In this report, we developed a high-throughput screening system to identify small-molecule inhibitors of p27(Kip1) degradation. This system was established by tagging Skp2 with fluorescent monomeric Azami Green (mAG) and CDK subunit 1 (Cks1) (mAGSkp2-Cks1) to bind to p27(Kip1) phosphopeptides. We identified two compounds that inhibited the interaction between mAGSkp2-Cks1 and p27(Kip1): linichlorin A and gentian violet. Further studies have shown that the compounds inhibit the ubiquitination of p27(Kip1) in vitro as well as p27(Kip1) degradation in HeLa cells. Notably, both compounds exhibited preferential antiproliferative activity against HeLa and tsFT210 cells compared with NIH3T3 cells and delayed the G1 phase progression in tsFT210 cells. Our approach indicates a potential strategy for restoring p27(Kip1) levels in human cancers.
© 2013 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23910095     DOI: 10.1111/cas.12246

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  14 in total

1.  Substituting threonine 187 with alanine in p27Kip1 prevents pituitary tumorigenesis by two-hit loss of Rb1 and enhances humoral immunity in old age.

Authors:  Hongling Zhao; Frederick Bauzon; Enguang Bi; J Jessica Yu; Hao Fu; Zhonglei Lu; Jinhua Cui; Hyungjun Jeon; Xingxing Zang; B Hilda Ye; Liang Zhu
Journal:  J Biol Chem       Date:  2015-01-12       Impact factor: 5.157

Review 2.  Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.

Authors:  R M Ruggeri; E Benevento; F De Cicco; B Fazzalari; E Guadagno; I Hasballa; M G Tarsitano; A M Isidori; A Colao; A Faggiano
Journal:  J Endocrinol Invest       Date:  2022-08-30       Impact factor: 5.467

Review 3.  Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2.

Authors:  Gareth Chin Khye Ang; Amogh Gupta; Uttam Surana; Shirlyn Xue Ling Yap; Reshma Taneja
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

Review 4.  Chemical probes of Skp2-mediated p27 ubiquitylation and degradation.

Authors:  Lea Lough; Dan Sherman; Eric Ni; Lauren M Young; Bing Hao; Timothy Cardozo
Journal:  Medchemcomm       Date:  2018-06-11       Impact factor: 3.597

Review 5.  CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity.

Authors:  Patrizia Bonelli; Franca Maria Tuccillo; Antonella Borrelli; Antonietta Schiattarella; Franco Maria Buonaguro
Journal:  Biomed Res Int       Date:  2014-01-29       Impact factor: 3.411

Review 6.  Emerging Roles of SKP2 in Cancer Drug Resistance.

Authors:  Ting Wu; Xinsheng Gu; Hongmei Cui
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

Review 7.  The Skp2 Pathway: A Critical Target for Cancer Therapy.

Authors:  Zhen Cai; Asad Moten; Danni Peng; Che-Chia Hsu; Bo-Syong Pan; Rajeshkumar Manne; Hong-Yu Li; Hui-Kuan Lin
Journal:  Semin Cancer Biol       Date:  2020-02-01       Impact factor: 17.012

Review 8.  Antitumor mechanisms when pRb and p53 are genetically inactivated.

Authors:  L Zhu; Z Lu; H Zhao
Journal:  Oncogene       Date:  2014-12-08       Impact factor: 9.867

9.  Interferon-γ-induced p27KIP1 binds to and targets MYC for proteasome-mediated degradation.

Authors:  Fuad Bahram; Per Hydbring; Susanna Tronnersjö; Siti Mariam Zakaria; Oliver Frings; Sara Fahlén; Helén Nilsson; Jacob Goodwin; Natalie von der Lehr; Yingtao Su; Bernhard Lüscher; Alina Castell; Lars-Gunnar Larsson
Journal:  Oncotarget       Date:  2016-01-19

10.  Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma.

Authors:  Li-Ling Luo; Lei Zhao; Ying-Xue Wang; Xiao-Peng Tian; Mian Xi; Jing-Xian Shen; Li-Ru He; Qiao-Qiao Li; Shi-Liang Liu; Peng Zhang; Dan Xie; Meng-Zhong Liu
Journal:  Sci Rep       Date:  2015-12-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.